Description of the Diagnostic Medical share buyback program

Diagnostic Medical announces a share buyback program in compliance with European and French regulations. This program, subject to approval by the General Meeting scheduled for June 15, 2026, would allow the repurchase of up to 10% of the company's share capital, or 2,668,679 shares, at a maximum price of €2.50 per share.

The total amount allocated to this program could reach €6,671,697.50. The Board of Directors will handle the share buybacks, which may be carried out through various means, including block acquisitions. The company may also use derivative instruments, subject to regulations.

This program aims to achieve several objectives: to support share liquidity, to preserve shares for potential future transactions, to cover employee stock option plans, and to allow for share cancellations. The 18-month program will begin after approval by the Annual General Meeting.